Dermapharm 9M 2026 adjusted EBITDA rises 5% to EUR 248.1 million

• Dermapharm’s nine-month 2026 profit fell to EUR 93.28 million, while revenue rose to EUR 884.37 million versus a year earlier.
• Operating profit climbed 14% to EUR 193.27 million; impairment expenses on financial assets totaled EUR 30 million.
• Operating cash flow increased 10% to EUR 148.61 million compared with the first nine months of 2025.
• Revenue growth benefited from initial contributions from Mucos and F. Trenka, while portfolio optimization reduced parallel-import revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermapharm Holding SE published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.